DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/89854d/boehringer_ingelhe) has announced the addition of the "Boehringer Ingelheim Partnering Guide 2008" company profile to their offering.

The Boehringer Ingelheim Partnering Guide 2008 provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Boehringer Ingelheim company profile

Company – therapy activity, partnering interests and partnering activity matrix

Marketed therapies

Pipeline therapies

Partnering interests

Partnering activities

Partnering contact listings

Key networking events

Boehringer Ingelheim partnering contracts

This report provides all the information you require to better understand Boehringer Ingelheim and its partnering interests and activities over the past five years.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, deal makers will effectively and efficiently determine the suitablility of Boehringer Ingelheim as a prospective partner, their business development objectives, interests and recent partnering activity, key partnering contacts, and partnering contract documents signed with their recent partners.

The report provides a firm basis for initial due diligence into Boehringer Ingelheim as a prospective partner company.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2007 pharmaceutical revenues.

Chapter 3 analyses the most active dealmakers between 2005 and 2007 in M&A and partnering deals announced, whilst chapter 4 identifies the top deals of 2005-7 according to reported deal size.

Chapter 5 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 6 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

Chapter 7 provides a series of matrices that summarize the company’s activity in terms of marketed and pipeline products, partnering interests and partnering activity by therapeutic area.

The main body of the report is provided in chapter 8. An in-depth profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The company profile is also provided with a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type – therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

In summary, the report provides the user with the tools to make successful contact with the right bigpharma partners effectively and efficiently.

Key benefits

Boehringer Ingelheim Partnering Guide 2008 report provides the user with the following key benefits:

- Detailed company profile of the company

- In-depth marketed and pipeline product activity for the company

- Partnering interests and therapy focus revealed

- Partnering activity since 2000 – number of deals per year

- Partnering activity for 2005-2008

- - Activity by deal type

- - Activity by phase of development

- - Activity by therapeutic area

- - List of recent partner companies

- Comprehensive access to actual contracts entered into by the company and its partners*

- Insight into the terms included in a partnering agreement

- Understand the key deal terms the company has agreed in previous deals

- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Boehringer Ingelheim Partnering Guide 2008 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the company, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.

Boehringer Ingelheim Partnering Guide 2008 includes:

- Detailed company profile including:

- - Full contact details

- - Business developer contact details including name, title, email and telephone (where available)

- - Marketed indications

- - Pipeline indications

- - Partnering interests and indications

- - Partnering activity since 2000

- - Current partner companies since 2005

- - Partnering activity since 2005 by:

- - - Deal type

- - - Stage of development

- - - Therapy area

- Numerous charts showing the dealmaking activity of the company since 2005

- The tools to enable effective and efficient preparation for partnering negotiation with the company

- Listing of contract documents between the company and its partners

- The leading M&A and partnering deals by value 2005-8

- Most active M&A and partnering dealmakers 2005-8

The Boehringer Ingelheim Partnering Guide 2008 report also provides comprehensive access to available contract documents for the company.

Analyzing actual company agreements allows assessment of the following:

- - What is actually granted by the agreement to the partner company?

- - What exclusivity is granted?

- - What is the payment structure for the deal?

- - How are sales and payments audited?

- - What is the deal term?

- - How are the key terms of the agreement defined?

- - How are IPRs handled and owned?

- - Who is responsible for commercialization?

- - Who is responsible for development, supply, and manufacture?

- - How is confidentiality and publication managed?

- - How are disputes to be resolved?

- - Under what conditions can the deal be terminated?

- - What happens when there is a change of ownership?

- - What sublicensing and subscontracting provisions have been agreed?

- - Which boilerplate clauses does the company insist upon?

- - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

- - Which jurisdiction does the company insist upon for agreement law?

*Subject to being published via regulatory requirements of the Securities Exchange Commission.

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Bigpharma – The Top 50

Chapter 3 – Most active bigpharma dealmakers

3.1 Bigpharma M&A activity

3.2 Bigpharma partnering

Chapter 4 – Top bigpharma deals – 2000-7

4.1 Bigpharma M&A

4.2 Bigpharma partnering

Chapter 5 – Submitting Opportunities to Bigpharma such as Boehringer Ingelheim

5.1 How to submit an opportunity

5.2 Opportunity submission template

5.3 Sending emails

5.4 Face to face at partnering events

5.5 Online submission forms

Chapter 6 – Forthcoming bigpharma partnering events

6.1 Forthcoming events

Chapter 7 – Boehringer Ingelheim – therapy locator

7.1 How to use the therapy matrix tables

7.2 Therapeutic area definitions

7.3 Boehringer Ingelheim – Therapeutic target matrix – marketed and pipeline compounds

7.5 Boehringer Ingelheim – Therapeutic target matrix – expressed partnering interests

7.6 Boehringer Ingelheim – Therapeutic target matrix – recent deals – 2005-2007

Chapter 8 – Bigpharma Company Profiles

8.1 How to use company profiles

8.2 Field definitions

8.3 Boehringer Ingelheim company profile

Company contact details

Subsidiary companies

Primary therapy areas

Business development contacts

Company description

Marketed therapeutic indications

Pipeline (phase I-III) therapeutic indications

Partnering interests

Partnering interests - therapeutic indications

Partnering frequency per annum - 2000-2008

Current partner companies (2005-8)

Recent deals 2005-2008

- By deal type

- By stage of development

- By therapy area

Contract documents available online - link direct to each document

Figures in report

Figure 1: Bigpharma – top 50 by pharma revenues 2007

Figure 2: Leading Bigpharma M&A companies, 2005-7

Figure 3: Leading Bigpharma partnering companies, 2005-7

Figure 4: Leading M&A deals involving bigpharma by value, 2005-7

Figure 5: Leading partnering deals by value, 2005-7

Figure 6: Typical partnering opportunity submission template

Figure 7: Partnering events 2008-9

Figure 8: Therapeutic area definitions

Figure 9: Therapeutic target matrix – marketed and pipeline compounds

Figure 10: Therapeutic target matrix – expressed partnering interests

Figure 11: Therapeutic target matrix – recent deals 2005-7

Figure 12: Company profile template and definitions used in report

Figure 13: Boehringer Ingelheim – Dealmaking frequency 2000-2007

Figure 14: Boehringer Ingelheim – recent deals (2005-2008) by deal type

Figure 15: Boehringer Ingelheim – recent deals (2005 – 2008) by stage of development

Figure 16: Boehringer Ingelheim – recent deals (2005 – 2008) by therapy area

Figure 17: Recent Boehringer Ingelheim partnering deals (2003-2008) where contract document available

Figure 18: Online partnering resources

For more information visit http://www.researchandmarkets.com/research/89854d/boehringer_ingelhe

Research and Markets
Laura Wood
Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com